H7N9 VLP influenza vaccine (Novavax)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameH7N9 VLP influenza vaccine (Novavax)

Drug Alias NameA(H7N9) influenza vaccine candidateH7N9 VLP vaccineA (H7N9) vaccinePandemic H7N9 Influenza VLP vaccineH7N9 Virus-Like Particle (VLP) Influenza vaccine (recombinant) +[6]

ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Genetically engineered subunit vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsInfluenza in BirdsInfluenza, Human

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Massachusetts Medical School Novavax

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovavax

Active IndicationsN/A

Inactive IndicationsInfluenza in BirdsInfluenza, Human

Other Information

ATC CodeN/A